BofA analyst Geoff Meacham lowered the firm’s price target on Johnson & Johnson to $170 from $180 and keeps a Neutral rating on the shares. Shares traded down despite a “solid” Q1 and unchanged reported guidance midpoint, which the firm suspects was due to disappointing Carvykti sales and the Vision business, the analyst tells investors. The firm, which thinks commercial execution from key growth franchises remains the focus and investor sentiment can improve on better-than-expected quarterly performance and pipeline readouts, argues that 2024 guidance looks “beatable,” but lowers its price target on a lower Carvykti sales outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- JNJ Earnings: Johnson & Johnson’s Q1 Earnings Beat Estimates
- Options Volatility and Implied Earnings Moves Today, April 16, 2024
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, April 15 – April 19, 2024
- Mind Medicine initiated with an Outperform at Leerink